Entry Point Capital, LLC Ab Cellera Biologics Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 168,682 shares of ABCL stock, worth $403,149. This represents 0.22% of its overall portfolio holdings.
Number of Shares
168,682
Previous 117,158
43.98%
Holding current value
$403,149
Previous $303,000
63.04%
% of portfolio
0.22%
Previous 0.18%
Shares
3 transactions
Others Institutions Holding ABCL
# of Institutions
165Shares Held
120MCall Options Held
233KPut Options Held
339K-
Baker Bros. Advisors LP New York, NY27.5MShares$65.8 Million0.89% of portfolio
-
Baillie Gifford & CO12.2MShares$29.2 Million0.03% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$25.4 Million0.04% of portfolio
-
Capital World Investors Los Angeles, CA7.93MShares$19 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX7.35MShares$17.6 Million6.4% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $681M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...